黄葵胶囊联合羟苯磺酸钙治疗早期糖尿病肾病的疗效观察

摘要

目的：观察黄葵胶囊联合羟苯磺酸钙治疗早期糖尿病肾病（DN）的疗效。方法将96例早期DN患者，随机分为治疗组48例和对照组48例。两组同时均给予羟苯磺酸钙治疗，治疗组加用黄葵胶囊，疗程为12周，比较两组治疗前后测定的尿素氮（BUN）、血肌酐（Scr）、胆固醇（TC）、甘油三酯（TG）、24 h尿蛋白排泄率（UAER）以及两组患者的不良反应发生状况。结果治疗疗程结束后，两组BUN、Scr、TC、TG、UAER均有明显降低（P＜0.05），但治疗组下降更为显著（P＜0.05）。结论黄葵胶囊联合羟苯磺酸钙应用能明显降低早期DN患者的BUN、Scr、TC、TG、UAER，延缓患者的病情发展，不良反应无明显变化。%Objective To observe the efficacy of HuangKui capsule plus calcium dobesilate in treatment of early diabetic nephrosis(DN).Methods 96 cases of early diabetic nephrosis patients were randomly divided into 2 groups, one(treatment group) with HuangKui capsule plus calcium dobesilate and the other(control group) with calcium dobesilate alone. The course of treatment was 12 weeks in two groups. Urea nitrogen(BUN), creatinine(Scr), cholesterol (TC), triglyceride(TG), 24 hours urinary protein excretion rate(UAER) and drug adverse reactions were compared respectively in two groups before and after the treatment.Results After the treatment, BUN, Scr, TC, TG and UAER in two groups were significantly reduced(P<0.05), But the decline in the treatment group was more significant(P<0.05).Conclusion Huangkui capsule combined with calcium dobesilate can significantly reduce BUN, Scr, TC, TG and UAER in the patients with early DN, delay the progression of the patient's condition. There was no significant change in drug adverse reactions. It is worthy of clinical application.